280 related articles for article (PubMed ID: 21270612)
1. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
Harter P; Sehouli J; Reuss A; Hasenburg A; Scambia G; Cibula D; Mahner S; Vergote I; Reinthaller A; Burges A; Hanker L; Pölcher M; Kurzeder C; Canzler U; Petry KU; Obermair A; Petru E; Schmalfeldt B; Lorusso D; du Bois A
Int J Gynecol Cancer; 2011 Feb; 21(2):289-95. PubMed ID: 21270612
[TBL] [Abstract][Full Text] [Related]
2. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
[TBL] [Abstract][Full Text] [Related]
3. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
van de Laar R; Massuger LF; Van Gorp T; IntHout J; Zusterzeel PL; Kruitwagen RF
Gynecol Oncol; 2015 May; 137(2):210-5. PubMed ID: 25677063
[TBL] [Abstract][Full Text] [Related]
4. AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer.
Muallem MZ; Gasimli K; Richter R; Almuheimid J; Nasser S; Braicu EI; Sehouli J
Anticancer Res; 2015 Jun; 35(6):3423-9. PubMed ID: 26026105
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer.
Harter P; Beutel B; Alesina PF; Lorenz D; Boergers A; Heitz F; Hils R; Kurzeder C; Traut A; du Bois A
Gynecol Oncol; 2014 Mar; 132(3):537-41. PubMed ID: 24462732
[TBL] [Abstract][Full Text] [Related]
6. Secondary complete cytoreduction in recurrent ovarian cancer: benefit of optimal patient selection using scoring system.
Laas E; Luyckx M; De Cuypere M; Selle F; Daraï E; Querleu D; Rouzier R; Chéreau E
Int J Gynecol Cancer; 2014 Feb; 24(2):238-46. PubMed ID: 24457552
[TBL] [Abstract][Full Text] [Related]
7. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Harter P; Sehouli J; Vergote I; Ferron G; Reuss A; Meier W; Greggi S; Mosgaard BJ; Selle F; Guyon F; Pomel C; Lécuru F; Zang R; Avall-Lundqvist E; Kim JW; Ponce J; Raspagliesi F; Kristensen G; Classe JM; Hillemanns P; Jensen P; Hasenburg A; Ghaem-Maghami S; Mirza MR; Lund B; Reinthaller A; Santaballa A; Olaitan A; Hilpert F; du Bois A;
N Engl J Med; 2021 Dec; 385(23):2123-2131. PubMed ID: 34874631
[TBL] [Abstract][Full Text] [Related]
8. [Recurrent ovarian cancer--qualification and results of surgical treatment].
Derlatkal P; Grabowska-Derlatka L; Jalinik K; Danska-Bidzińska A
Ginekol Pol; 2015 Dec; 86(12):902-6. PubMed ID: 26995939
[TBL] [Abstract][Full Text] [Related]
9. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses.
Bogani G; Tagliabue E; Signorelli M; Ditto A; Martinelli F; Chiappa V; Mosca L; Sabatucci I; Leone Roberti Maggiore U; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2018 May; 29(3):e40. PubMed ID: 29533023
[TBL] [Abstract][Full Text] [Related]
10. Positive DESKTOP and Tian Scores Systems Are Adequate to Predict Optimal (R0) Secondary Debulking Surgery in Ovarian Cancer, But a Negative Score Does Not Preclude Secondary Surgery.
Laga T; Lambrechts S; Laenen A; Van Nieuwenhuysen E; Han SN; Vergote I
Int J Gynecol Cancer; 2018 May; 28(4):721-728. PubMed ID: 29561300
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer.
Lenhard SM; Burges A; Johnson TR; Kirschenhofer A; Bruns C; Linke R; Friese K
Eur J Obstet Gynecol Reprod Biol; 2008 Oct; 140(2):263-8. PubMed ID: 18614272
[TBL] [Abstract][Full Text] [Related]
12. Surgery for recurrent ovarian cancer.
Heitz F; du Bois A; Kurzeder C; Pfisterer J; Barinoff J; Grabowski J; Hilpert F; Mahner S; Harter P
Womens Health (Lond); 2011 Sep; 7(5):529-35. PubMed ID: 21879821
[TBL] [Abstract][Full Text] [Related]
13. When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M; Harter P; Heitz F; du Bois A
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):493-497. PubMed ID: 29743148
[TBL] [Abstract][Full Text] [Related]
14. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
15. Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
Janco JM; Kumar A; Weaver AL; McGree ME; Cliby WA
Gynecol Oncol; 2016 Apr; 141(1):140-7. PubMed ID: 26836496
[TBL] [Abstract][Full Text] [Related]
16. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis.
Harter P; Hahmann M; Lueck HJ; Poelcher M; Wimberger P; Ortmann O; Canzler U; Richter B; Wagner U; Hasenburg A; Burges A; Loibl S; Meier W; Huober J; Fink D; Schroeder W; Muenstedt K; Schmalfeldt B; Emons G; du Bois A
Ann Surg Oncol; 2009 May; 16(5):1324-30. PubMed ID: 19225844
[TBL] [Abstract][Full Text] [Related]
17. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for complete debulking in first- and second-line ovarian cancer.
Harter P; Hilpert F; Mahner S; Kommoss S; Heitz F; Pfisterer J; du Bois A
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S14-7. PubMed ID: 19955907
[TBL] [Abstract][Full Text] [Related]
20. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
Tian WJ; Chi DS; Sehouli J; Tropé CG; Jiang R; Ayhan A; Cormio G; Xing Y; Breitbach GP; Braicu EI; Rabbitt CA; Oksefjell H; Fotopoulou C; Meerpohl HG; du Bois A; Berek JS; Zang RY; Harter P
Ann Surg Oncol; 2012 Feb; 19(2):597-604. PubMed ID: 21732142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
